Alerts will be sent to your verified email
Verify EmailPGHL
|
Procter&Gamble Healt
|
Strides Pharma Scien
|
Marksans Pharma
|
|
|---|---|---|---|
|
Operational Metrics
|
|||
|
Pharmaceuticals
|
|||
|
Domestic Sales Growth - YoY
|
20.1 % | n/a | n/a |
|
Financials
|
|||
|
5 yr Average ROE
|
36.03 % | 30.1 % | 17.57 % |
|
5yr average Equity Multiplier
|
1.79 | 2.62 | 1.33 |
|
5yr Average Asset Turnover Ratio
|
0.77 | 0.6 | 0.9 |
|
5yr Avg Net Profit Margin
|
19.19 % | 12.9 % | 14.56 % |
|
Price to Book
|
20.13 | 3.34 | 3.96 |
|
P/E
|
32.3 | 18.68 | 28.63 |
|
5yr Avg Cash Conversion Cycle
|
-155.74 Days | -51.45 Days | 71.65 Days |
|
Inventory Days
|
36.01 Days | 69.05 Days | 89.77 Days |
|
Days Receivable
|
40.92 Days | 60.35 Days | 65.99 Days |
|
Days Payable
|
215.28 Days | 225.58 Days | 88.81 Days |
|
5yr Average Interest Coverage Ratio
|
500.05 | 0.72 | 38.03 |
|
5yr Avg ROCE
|
30.21 % | 10.5 % | 21.95 % |
|
5yr Avg Operating Profit Margin
|
27.53 % | 12.17 % | 20.32 % |
|
5 yr average Debt to Equity
|
0.0 | 1.01 | 0.02 |
|
5yr CAGR Net Profit
|
4.02 % | 68.01 % | 10.03 % |
|
5yr Average Return on Assets
|
15.5 % | 10.97 % | 13.19 % |
|
Shareholdings
|
|||
|
Promoter Holding
|
51.82 % | 27.91 % | 43.87 % |
|
Share Pledged by Promoters
|
0.0 | 27.27 % | 0.0 |
|
Change in Promoter Holding (3 Yrs)
|
0.0 | -0.36 % | 0.02 % |
|
Change in Mutual Fund Holding (3 Yrs)
|
2.86 % | -2.58 % | 3.8 % |
|
Procter&Gamble Healt
|
Strides Pharma Scien
|
Marksans Pharma
|
|
|---|---|---|---|
|
Segment Break-Up
|
Segment Break-Up
|
-
|
-
|
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
|
Drug Delivery Break-Up
|
Drug Delivery Break-Up
|
-
|
-
|
|
Therapeutic Area Break-Up
|
Therapeutic Area Break-Up
|
-
|
-
|
|
Asset Break-Up
|
Asset Break-Up
|
Asset Break-Up
|
-
|